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Abstract
Background: Vitamin D deficiency has been proposed to contribute to the development of malabsorption diseases.
Despite this, the vitamin D status of these patients is often neglected. The objective of the present work was to compare
the absorption of vitamin D3 through the oral route by comparing a 1000 IU soft gelatin capsule and a 500 IU buccal
spray (delivering 1000 IU in two spray shots) in healthy subjects and in patients with malabsorption disease.
Methods: An open label, randomized, two-periods, two-way cross over study was conducted, first in healthy subjects
(n = 20) and then in patients with malabsorption syndrome (n = 20). The study participants were equally divided and
received either of the treatments (buccal spray, n = 7; soft gelatin capsule, n = 7; control, n = 6) in Period I for 30 days.
After washout of another 30 days, the treatments were changed in crossover fashion in Period II. Fasting blood samples
were collected to measure baseline 25-hydroxyvitamin D [25(OH)D] levels in all participants at day 0 (Screening visit),
day 30 (completion of period I), day 60 (end of wash out and initiation of period II) and day 90 (completion of period
II). Safety was evaluated by hematology and biochemistry analyses. Statistical analyses was performed using differences
of mean and percentage change from baseline of 25(OH)D levels between two formulation by two tailed Paired t-test
with 95 % confidence interval.
Results: In healthy subjects, the mean increase in serum 25(OH)D concentration was 4.06 (95 % CI 3.41, 4.71) ng/ml in
soft gelatin capsule group and 8.0 (95 % CI 6.86, 9.13) ng/ml in buccal spray group after 30 days treatment (p < 0.0001).
In patients with malabsorption disease, the mean increase in serum 25(OH)D concentration was 3.96 (95 % CI 2.37,
5.56) ng/ml in soft gelatin capsule group and 10.46 (95 % CI 6.89, 14.03) ng/ml in buccal spray group (p < 0.0001).
Conclusion: It can be concluded from the results that the buccal spray produced a significantly higher mean serum
25(OH)D concentration as compared to the soft gelatin capsule, in both healthy subjects as well as in patients with
malabsorption syndrome over a period of 30 days administration in a two way cross over study. Treatments were well
tolerated by both subject groups
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Introduction
Vitamin D is essential for active intestinal calcium ab-
sorption and plays a central role in maintaining calcium
homeostasis and skeletal integrity. It is derived mainly
from cutaneous synthesis in the presence of ultraviolet
sunlight while dietary intake constitutes a minor frac-
tion [1]. Vitamin D deficiency is a common problem
through the world [2, 3] and is assessed by low serum
concentration of the major circulating metabolite 25-
hydroxyvitamin D (25(OH)D) [4, 5]. The prevention of
vitamin D deficiency and insufficiency remains a priority
of international health services [6–8]. Vitamin D defi-
ciency has been proposed to contribute to the develop-
ment of intestinal bowel diseases like Crohn's disease,
steatorrhea and ulcerative colitis [9]. Conversely, people
who have such illnesses have a reduced absorption of
vitamin D3 through the intestine [10, 11]. In addition,
osteomalacia occurs in patients with a wide variety of dis-
orders affecting the stomach and small bowel, especially
when associated with steatorrhea. The pathogenesis of this
osteomalacia has in part been explained by malabsorption
in vitamin D [9]. Earlier reports show that orally adminis-
tered tritiated vitamin D3 was malabsorbed in patients
with celiac disease, biliary obstruction or pancreatic dis-
ease [12]. The pathogenesis of vitamin D deficiency in
these patients remains unclear but it is thought to result
primarily from fat soluble vitamin malabsorption due to
the presence of intestinal disease conditions
Despite vitamin D malabsorption in patients with gastro-
intestinal or liver disease, the vitamin status of these pa-
tients is often neglected. Although vitamin D supplements
are often prescribed, adequate absorption of these formula-
tions has not been documented [10]. Vitamin D is known
to be liposoluble, and its relative bioavailability could result
in unfavorable conditions when administered in solid form
(capsule), since the process of its release is a factor limiting
the rate of absorption, bearing in mind that bioavailability
is related not only to the pharmaceutically active mole-
cules, but also, to the formulation and excipients used.
Vitamin D3 taken by oral route (peroral delivery) is
absorbed in the intestine, where the lining of the digestive
tract is aqueous in nature. Therefore vitamin D3, a fat-
soluble molecule, in order to be absorbed, must be made
water soluble in the intestine. This is accomplished in two
steps: emulsification of vitamin D3 in the intestinal
lumen, through the action of bile salts, forming small
droplets which are dispersed and incorporated into
micelles-complex aggregates formed by the interaction
of free fatty acids, monoglycerides, and bile salts.
Micelles are sufficiently water-soluble to access the
intestinal brush border where upon the vitamin D3
content is released and then absorbed [13].
When sprayed inside the mouth, the fine micro sized
droplets of vitamin D3 are believed to be quickly and
completely absorbed through the buccal mucosa into the
numerous capillaries and veins lying close to the tissue sur-
face [13]. Considering the possibility of reduced vitamin D
absorption in healthy subjects and even in patients with
malabsorption syndrome, a buccal spray formulation was
developed. Therefore, the objective of the present work
was to compare the absorption of vitamin D3 through the
oral route (soft gelatin capsule form) and buccal spray in
healthy subjects and patients with intestinal malabsorption
syndrome.
Methods
Study design and patients
An open label, randomized, two-periods, two-way cross
over study was conducted, first in healthy subjects and
then in patients with malabsorption syndrome, with a simi-
lar study design except the presence of disease status in pa-
tients with malabsorption syndrome. After approval from
the Spandan-IEC ethics committee (registration no: ECR/
67/Indt/GJ/2013), the informed consent of study partici-
pants were taken and the formulation was administered for
30 days in period I where half of the subjects and patients
(collectively participants) received capsule formulation and
half of the participants received buccal spray formulation.
After completion of treatment in period I, all participants
were given 30 days wash out before initiating period II
where treatment has changed in cross over fashion, i.e. the
participants who received capsule formulation in period I
have received buccal spray in period II and vice versa. The
clinical study was registered in a centralized clinical trial
registry of India (CTRI) before initiating the enrollment of
the first patient in the study (CTRI/2013/06/003770).
The inclusion criteria were as follows: subjects of either
sex between 18 and 65 years of age, with a Body Mass
Index (BMI) between 18.0 and 30.0 kg/m2, and the ability
to comply with study procedures in the opinion of the in-
vestigators. For healthy subjects: no history of liver, kidney
or cardiovascular disease, or of any other medical condi-
tions or medications likely to affect vitamin D3 absorption
or metabolism. For patients with malabsorption syndrome:
confirmed diagnosis of any one of the following malab-
sorption disease conditions like ulcerative colitis, Crohn’s
disease or steatorrhea. Patient with history of above dis-
eases, who are on therapy, were selected for the screening.
In these patients, malabsorption syndrome was diagnosed
by clinical symptoms like abdominal pain, vomiting, diar-
rhea, and subcutaneous fat loss together with blood tests
like haematology and biochemistry. Stool examination was
also performed for all patients to confirm rectal bleeding,
presence of occult blood, infectious organisms, or fat.
Finally, colonoscopy was performed in all patients to
objectively assess the extent of inflammation to confirm
the diagnosis. The exclusion criteria were as follows:
systemic inflammatory or malignant disease; hepatic or
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renal failure; uncontrolled hypo- or hyperthyroidism, or the
use of drugs that are known to affect bone metabolism such
as bisphosphonates, glucocorticoids and anti-convulsants.
A pregnant or desired to be pregnant woman during study
period was also excluded.
Data collected at baseline
Each participant completed a self-administered ques-
tionnaire before enrollment. During completion of the
questionnaire, they had the possibility to ask for assist-
ance (i.e. clarification of question or any other issue)
from one of the project leaders. The questionnaire in-
cluded questions about usual intake of vitamin D con-
taining foods, clothing and sun exposure habits, as
well as height & weight, date of birth, and education.
Body mass index was derived as wt/ht2 (kg/m2). Blood
pressure was measured through sphygmomanometer
and vitals (heart rate, body temperature) were also re-
corded for safety purposes.
Collection and analyses of blood samples
Fasting blood samples were collected to measure baseline
25(OH)D levels in all the participants at day 0 (Screening
visit), day 30 (completion of period I), day 60 (end of wash
out and initiation of period II) and day 90 (completion of
period II). Blood samples were centrifuged (15 min;
2000 g at 4 °C) within 30 min of blood collection and
separated serum samples were immediately frozen. Serum
samples were stored at −20 °C until analyzed. Serum
25(OH)D levels were measured by Electrochemilumines-
cence (ECLIA) assay method. This assay was carried
out through quantitative determinations of total 25-
hydroxyvitamin D in serum samples using a standard
kit available from Roche diagnostics GmbH, Germany.
All analyses were done in a central independent clinical
analysis laboratory (APL Institute of Clinical Laboratory
& Research Pvt. Ltd., Ahmedabad, India). The kit has a
limit of detection of 3 ng/mL and has a linearity of 0.0 to
60.0 ng/mL. The intra-assay and inter-assay co-efficient of
variation were 4 % and 6 %, respectively. Elecsys e-
immunoassay analyzers were used for this assay.
Safety parameters were evaluated including hematology
analyses (complete blood counts), biochemical analyses
(serum creatinine, total bilirubin, urea, SGOT, SGPT, alka-
line phosphates, calcium) and urine was collected for urine
routine and microbiological analyses at screening visit (day
0) and at the end of period II visit (day 90).
Intervention randomization and compliance
Randomization and group allocation:
The participants were enrolled at two different hospital
sites in India; one physician’s site where all healthy subjects
were recruited and a gastroenterologist’s site where all pa-
tients with intestinal malabsorption were recruited. Out of
the forty-eight participants who met the eligibility criteria,
forty (twenty healthy and twenty patients) had agreed to
participate and were found eligible, signed a written con-
sent form, and completed a self administered questionnaire
concerning usual diet and sun exposure. Subsequently, a
venous blood sample was drawn, and a participant received
a sealed, non-transparent envelope with the allocated treat-
ment intervention. The randomization procedure was per-
formed beforehand by a statistician by block randomization
with blocks of two to one ratio, where the first two partici-
pants were randomly given each treatment and a third
participant served as a control and didn’t receive any treat-
ment. The participants were allocated to the interventions
as they visited the clinic i.e. the first subject was allocated
to buccal spray group, second to soft gelatin capsule group
and third to the control group. This was done in order to
distribute the participants equally in the two interventions
(Group I and Group III) and half of the participants served
as a control (Group II and Group IV).
Twenty healthy subjects enrolled for the study were
recruited at a physician’s site. They were randomized
and enrolled into group I and II: fourteen subjects were
enrolled for vitamin D3 treatment and labeled as group I
(healthy subjects), while every third subject (total six
subjects) were not given any treatment (labeled as group
II) and acted as the control for group I.
The twenty patients with confirmed diagnosis of malab-
sorption syndromes (nine with ulcerative colitis, four with
Crohn’s disease and seven with steatorrhea) were recruited
at a gastroenterologist’s hospital site. Fourteen subjects
were enrolled for vitamin D3 treatment and labeled as
group III (patients with malabsorption syndrome), while
every third subject (total six subjects) were not given any
treatment (labeled as group IV) and acted as the control
for group III. All patients continued to take their treat-
ment for ulcerative colitis, Crohn’s disease and steatorrhea
as prescribed by gastroenterologists.
Treatment allocation was assigned to each participant
according to their number of sequence of attendance at
the blood sampling. Treatment allocation was concealed in
envelopes numbered in ascending order that they met.
Study personnel involved in recruitment and data collec-
tion were blinded to the participant’s treatment allocation.
All participants were instructed to maintain their routine
lifestyle including diet habits and sun exposure during the
entire study period, to minimize interference with the daily
routine.
Intervention
The buccal spray and soft gelatin capsules containing
vitamin D3 were supplied by Pharma Base, India (a sub-
sidiary of Pharma Base SA, Switzerland). The soft gelatin
capsule formulation was purchased from the Indian market.
The analysis of both the formulations was done in triplicate
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according to the method described in European Pharmaco-
peia at an independent analytical laboratory (Oasis Testing
House, Ahmedabad, India). The soft gelatin capsule formu-
lation had a label content of 1000 IU per capsule and the
buccal spray formulation had a label content of 500 IU/
spray shot.
All participants in group I & III were randomized to re-
ceive either the vitamin D3 buccal spray (2 sprays each of
500 IU) or soft gelatin capsule containing vitamin D3
(1000 IU) for 30 days. Of the fourteen subjects in each
group, half received buccal spray and half received soft
gelatin capsule. This was considered as period I of the
study. After the completion of the 30-day treatment, all
participants were given a 30-day washout. The next treat-
ment in period II was changed in a crossover fashion;
those participants who had received the buccal spray for-
mulation (vitamin D3) in period I received the soft gelatin
capsule formulation in period II and vice versa. The treat-
ment in period II continued in group I and group III par-
ticipants for the next 30 days. The detailed study flow
chart is described in Fig. 1.
Compliance
All participants were instructed to take the two buccal
sprays and one soft gelatin capsule every day irrespective
of the period of the study. Formulation for 7 days was
Fig. 1 Study flow chart
Satia et al. Nutrition Journal  (2015) 14:114 Page 4 of 9
handed over to each participants under group I & III at
baseline, along with the compliance form. The partici-
pants were instructed to mark the intake and time of in-
take of number of spray shots or capsule of each day of
the study period, as well as to note any extraordinary
event that occurred during the period (forgetting to take a
spray shot or capsule). If forgetting to take spray shot or
capsule, the participants were instructed to take a double
dose on the following day, in order to take altogether 60
spray shots or 30 capsules during the study periods. The
participants were recommended to take spray shots or
capsules after the main meal of the day. However, partici-
pants were not instructed to standardize meals or time be-
tween meals. All participants were also instructed not to
change their daily routine, meal habits, as well as their sun
exposure. This was done to minimize interference with
daily routine and thus maximizing compliance with taking
study medication. All participants in group I and III were
instructed to visit the site every week to check compliance
with the intake of study medication. Participants in con-
trol groups (Group II and Group IV) were instructed to
visit their respective clinic after 30 days for their blood
sample collection.
All participants who received treatment were also
instructed to note any adverse events during the entire
90 days of the study which included period I, washout




The sample size of this crossover study was based on the
changes in 25(OH)D levels where goal was to detect: 1)
percent increase between pre-dose and post-dose levels
within treatments, and 2) to have significant difference of
percent change in 25(OH)D levels between the treatments.
To achieve type-I error rate of less than 5 % (2 tailed), a
sample size of 12 subjects in buccal spray group (healthy
or patients) was sufficient to provide a statistical power of
80 % to detect a clinically significant mean difference of
5 % in 25(OH)D levels.
Demographic and baseline characteristic
A descriptive statistics was applied for demographics; age
(years), weight (kg), body mass index (kg/m2); and were
presented as mean ± standard deviation.
Efficacy analysis
Statistical analyses were performed using GraphPad Prism
5, version 5.03 (GraphPad Software, Inc., CA, USA). Differ-
ences of mean and percentage change from baseline of
25(OH)D levels between two formulation groups, soft gel-
atin capsules and buccal spray, were evaluated using two
tailed Paired t-test with 95 % confidence interval separately
for both healthy subjects and patients with intestinal mal-
absorption. For comparison between control group and
either of the treatments, unpaired t-test with 95 % confi-
dence interval was used.
Safety analysis
The number and proportion of subjects with changes in
laboratory value (change from baseline to end of study
visit for complete blood count, serum creatinine, total
bilirubin, urea, SGOT, SGPT, alkaline phosphates and
calcium) was summarized and the difference was ana-
lyzed by chi –square test from normal to abnormal.
Results
Baseline characteristics:
In total, thirty eight individuals, thirteen healthy individuals
with six control and thirteen patients with malabsorption
syndrome with six control, fulfilled the eligibility criteria
and completed the study (Fig. 1). Two participants (one
healthy subject and one patient) reported vitamin D3 intake
compliance of less than 90 % and therefore were not con-
sidered for final analyses.
In healthy subjects, at baseline, 85 % (n = 12) of the sub-
jects had serum 25(OH)D concentration between 10 and
30 ng/ml, and one individual each (7.14 %) had serum
25(OH)D concentration >30 ng/ml and <10 ng/ml each in
the oral soft gelatin capsule group. While in the buccal
spray group, at baseline all subjects had serum 25(OH)D
concentration between 10 and 30 ng/ml. Similarly, in pa-
tients with malabsorption disease who received oral soft
gelatin capsules, at baseline 8 (57.14 %) patients had serum
25(OH)D concentration below 10 ng/ml, 5 (35.71 %) pa-
tients had serum 25(OH)D concentration between 10 and
20 ng/ml, and one individual (7.14 %) had serum 25(OH)D
concentration above 20 ng/ml. However, in the buccal
spray group, at baseline 9 (64.28 %) patients had serum
25(OH)D concentration below 10 ng/ml and 5 (35.71 %)
patients had serum 25(OH)D concentration between 10
and 20 ng/ml. There were no striking differences in base-
line characteristics between healthy individuals or patients
with malabsorption disease with their corresponding con-
trol groups (Table 1).
Effect of intervention
The control groups in each subject population were com-
pared with their corresponding treatment group. The
control groups for healthy subjects as well as patients with
malabsorption syndrome showed no change in 25(OH)D
concentration over a period of 30 days. The mean baseline
levels of 25(OH)D in healthy subjects was 18.25 ng/ml
and in patients with malabsorption syndrome was
11.7 ng/ml. These mean levels remained at 18.06 ng/ml
and 12.52 ng/ml after 30 days in healthy subjects and pa-
tients with malabsorption syndrome respectively (Fig. 2),
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which was statistically non-significant. When control
group in healthy subjects was compared with their cor-
responding treatment groups, it was found that the dif-
ference of mean between control group and buccal
spray group was 7.47 (95 % CI, 5.27, 9.67) which was sig-
nificant (p < 0.05), and the same between control group and
soft gelatin capsule group was 3.53 (95 % CI, 1.79, 5.28)
which was also statistically significant (p < 0.05). Similarly
in patients, the difference of mean between control group
and buccal spray group was 8.53 (95 % CI, 2.74, 14.31)
which was significant (p < 0.05), while the difference of
mean between control group and soft gelatin capsule group
was 2.03 (95 % CI, −1.44, 5.50) which was statistically not
significant. This shows that buccal spray was more effective
to increase mean 25(OH)D levels as compared to oral soft
gelatin capsule. Table 2 describes these data.
The efficacy of buccal spray and soft gelatin capsule to
increase the 25(OH)D levels after 30 days of administration
was evaluated and compared with each other. After 30 days
of administration, overall mean serum 25(OH)D concen-
tration in healthy subjects was 22.75 (sd 6.75) ng/ml as
compared to baseline value of 18.69 (sd 5.88) ng/ml in the
soft gelatin capsule group, with the mean increase of 4.06
(95 % CI 3.41, 4.71) ng/ml (Table 3). On the other hand, in
the buccal spray group, the mean serum 25(OH)D concen-
tration was 26.91 (sd 5.72) ng/ml as compared to baseline
value of 18.91 (sd 4.3) ng/ml, with the mean increase of 8.0
(95 % CI 6.86, 9.13) ng/ml (Fig. 2). The difference in mean
increase between both the groups was 3.95 (95 % CI 3.19,
4.69) which was statistically significant (p < 0.0001).
When calculated from baseline, the mean percentage
change in serum 25(OH)D concentration in healthy sub-
jects after 30 days treatment with soft gelatin capsule was
21.72 % (95 % CI 16.42, 24.42), while the same in buccal
spray group was 42.99 % (95 % CI 37.19, 48.79) with a
mean difference of 20.42 % (95 % CI 16.42, 24.42) between
two groups (p < 0.0001) (Table 3). A total of 11 (85 %) sub-
jects now had serum 25(OH)D concentration between 10
and 30 ng/ml, and two individuals (15.38 %) now had
serum 25(OH)D concentration >30 ng/ml in the soft gel-
atin capsule group. However, in the buccal spray group, 10
(75.88 %) subjects had serum 25(OH)D concentration be-
tween 10 and 30 ng/ml and 3 (23.1 %) subjects now had
serum 25(OH)D concentration >30 ng/ml.











N 14 6 14 6
Sex Male = 7, Female = 7 Male = 3, Female = 3 Male = 7, Female = 7 Male = 3, Female = 3
Age (Yrs) 36.21 ± 9.97 34.00 ± 6.42 39.93 ± 11.65 44.17 ± 5.56
(Range) (25–60) (25–42) (26–63) (38–53)
Height (cms) 159.86 ± 13.43 161.33 ± 14.12 162.29 ± 8.54 164.33 ± 8.55
BMI 23.39 ± 3.88 21.40 ± 2.39 21.48 ± 2.82 23.64 ± 3.02











Baseline After 30 days
treatment
Baseline After 30 days
treatment
Baseline After 30 days
Buccal Spray Soft Gelatin Capsule Control
Mean 25(OH)D level (ng/ml) in study subjects
Healthy Patients
Fig. 2 Mean 25(OH)D level in study subjects
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Similarly in patients with malabsorption syndrome,
overall mean serum 25(OH)D concentration after 30 days
of administration of soft gelatin capsule was 14.97 (sd
9.01) ng/ml as compared to baseline value of 11.01 (sd
6.43) ng/ml, with the mean increase of 3.96 (95 % CI
2.37, 5.56) ng/ml. While in buccal spray group, mean
serum 25(OH)D concentration was 20.47 (sd 7.89) ng/ml
as compared to baseline value of 10.01 (sd 4.29) ng/ml,
with the mean increase of 10.46(95 % CI 6.89, 14.03) ng/ml
(Fig. 2). The difference in mean increase between both the
groups was 6.50 (95 % CI 3.78, 9.22) which was statistically
significant (p < 0.0001).
The mean percentage change in serum 25(OH)D con-
centration in patients with malabsorption syndrome after
30 days treatment with soft gelatin capsule was 36.02 %
(95 % CI 30.42, 41.62), while the same value in buccal
spray group was 117.8 % (95 % CI 64.71, 170.8) with a
mean difference of 81.75 % (95 % CI 29.80, 133.7) between
the two treatments (p < 0.005). A total of four (31 %) sub-
jects now had serum 25(OH)D concentration below
10 ng/ml, eight (61 %) subjects now had serum 25(OH)D
concentration between 10 and 30 ng/ml, and one individ-
ual (7.7 %) had serum 25(OH)D concentration above
30 ng/ml. However, in the buccal spray group, only 7.7 %
Table 2 Comparison of 25(OH)D in control group and their corresponding treatment groups after 30 days
Comparison Difference of mean 95 % CI P Value
Healthy – Buccal Spray vs. Control 7.47 5.27 to 9.67 <0.0001
Healthy – Soft Gelatin Capsule vs. Control 3.53 1.79 to 5.28 0.0005
Patients – Buccal Spray vs. Control 8.53 2.74 to 14.31 0.0064
Patients – Soft Gelatin Capsule vs. Control 2.03 −1.44 to 5.50 0.2338
Table 3 Level of 25(OH)D in Healthy Subjects and Patients with malabsorption syndrome after 30 day administration of vitamin D3
buccal spray and soft gelatin capsule
Parameters Mean baseline value
in ng/ml
Mean value in ng/ml
after 30 day of treatment
Difference of mean Percentage mean increase
from baseline
Healthy Subjects
Soft gelatin Capsule Formulation
Mean 18.69 ± 5.88 22.75 ± 6.75 4.06 21.72 %
Range 9.25, 30.05 12.75, 35.52 2.5, 5.6 15.36, 37.79
n 13 13 13 13
95 % CI 15.14 to 22.24 18.67 to 24.42 3.41 to 4.71 16.42 to 24.42
Buccal Spray Formulation
Mean 18.91 ± 4.3 26.91 ± 5.72 7.995 42.99 %
Range 13.36, 26.82 19.6, 38.5 4.5, 11.67 29.21, 68.71
n 13 13 13 13
95 % CI 16.31 to 21.51 23.45 to 30.36 6.86 to 9.13 37.19 to 48.79
Patients with intestinal malabsorption syndrome
Soft gelatin Capsule Formulation
Mean 11.01 ± 6.43 14.97 ± 9.01 3.965 36.02 %
Range 2.9, 26.5 4.6, 36.89 1.06,10.39 24.62,58.73
n 13 13 13 13
95 % CI 7.12 to 14.89 9.52 to 20.42 2.37 to 5.56 30.42 to 41.62
Buccal Spray Formulation
Mean 10.01 ± 4.29 20.47 ± 7.89 10.46 117.8 %
Range 4.6, 18.85 9.8, 34.64 4.25, 27.44 61.31,381.1
n 13 13 13 13
95 % CI 7.42 to 12.6 15.7 to 25.24 6.89 to 14.03 64.71 to 170.8
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(1 subject) now had serum 25(OH)D concentration below
10 ng/ml, ten (76.9 %) subjects now had serum 25(OH)D
concentration between 10 and 30 ng/ml and two (15.4 %)
subjects now had serum 25(OH)D concentration more
than 30 ng/ml (Table 3).
Statistical considerations with respect to period,
sequence and power:
Statistical analyses were performed using SAS v9.2
(SAS Institute Inc, Cary, NC, USA) for the post-hoc
evaluation of sequence and period effect. The statistical
method adopted for this analysis was period + sequence +
Subject (sequence) + treatment. It was observed that there
is no significant difference in sequence effect in healthy
subjects (p = 0.5251) and in patients with malabsorption
syndrome (p = 0.0532). It was also revealed that there is
no statistically significant period effect in healthy subjects
(p = 0.6920) as well as in patients with malabsorption syn-
drome (p = 0.0715). The post-hoc power analyses with
intra-subject variability were also derived for both the
group of subjects. In healthy subjects, statistical power ob-
tained was 99.42 with an 11.81 % intra-subject variability.
While, in patients with malabsorption syndrome it was
81.62 with an intra-subject variability of 21.86 %.
Safety evaluation
There were no significant changes in any of the hematology
and biochemistry parameters studied. There are also no
notable changes in the vitals for any of the participants. No
adverse event reported after administration of the buccal
spray or soft gelatin capsule formulations of vitamin D3
during entire study period in healthy or patients with mal-
absorption disease and hence the product is considered
safe.
Discussion
Supplemental fat-soluble vitamin D is usually made
without determination of whether oral doses are ad-
equately absorbed. The evidence of vitamin D malabsorp-
tion (Osteomalacia, rickets, hypocalcaemia, or reduced
circulating concentration of 25(OH)D) persists despite
routine vitamin D supplementation in cystic fibrosis [14],
Crohn’s disease [15], Intestinal resection [16–19], ulcera-
tive colitis, liver disease [20–22] and other malabsorption
syndrome [23].
Many factors are involved in the absorption of vitamin D,
including gastric, pancreatic, and biliary secretions, micelle
formation, and diffusion through the unstirred water layer,
brush border membrane uptake, and transport out of the
intestinal cell [24, 25]. As vitamin D is a relatively non-
polar sterol, it must be solubilized by incorporation into a
bile salt micelle solution in order to be absorbed in the
aqueous phase [26]. This process is severely inhibited if
there is any interruption of normal pancreatic or biliary
secretion. As fat-soluble vitamins are fairly sensitive to
disturbances in lipid absorption, vitamin malabsorp-
tion may occur in conditions like steatorrhea, ulcera-
tive colitis, and Crohn’s disease. Serum concentrations
of 25-hydroxyvitamin D are good indicators of long
term vitamin D levels in the body but are insensitive to
single doses of vitamin D and do not rise out of the
normal range unless doses of vitamin D are chronically
administered [27].
Considering the malabsorption in intestinal disease and a
possible poor and complex absorption with oral formula-
tions, a novel nanoemulsion formulation of buccal spray
was developed where vitamin D3 is suspended in an aque-
ous base which can be easily absorbed through the mucosal
layer of the mouth. We compared the serum concentration
of vitamin D after 30 days administration with the soft
gelatin capsule and the aqueous based buccal spray formu-
lation. To the best of our knowledge, this is the first ran-
domized two way cross over trial comparing the increase in
25(OH)D levels in healthy adults and patients with intes-
tinal malabsorption receiving similar oral doses of two dif-
ferent formulations (per oral and buccal spray).
The analyses of baseline levels of study participants
showed that vitamin D deficiency was prevalent in both
healthy subjects and patients with intestinal malabsorp-
tion syndrome. However, patients were more vitamin D
deficient as compared to healthy subjects. Four weeks
administration of 1000 IU per day increased mean serum
25(OH)D in all treatment groups. In healthy subjects,
soft gelatin capsule increased serum 25(OH)D level by
22.5 % (Range 15.4 to 37.8 %), while the buccal spray in-
creased serum 25(OH)D level by 43 % (range 29.2 to
68.7. Similarly, in patients with intestinal malabsorption,
soft gelatin capsule increased serum 25(OH)D level by
36 % (range 24.6 to 58.7 %) and the buccal spray in-
creased serum 25(OH)D by 117.8 % (range 61.3 to
381.1 %).
The result implies that the buccal spray formulation had
a significantly higher mean increase in both the subject
groups, healthy subjects and patients with intestinal mal-
absorption syndrome. Interestingly, the mean increase
was much higher in the patients group as compared to
the healthy subjects group. This may be because increase
in serum 25(OH)D after supplementation is known to be
inversely related to baseline 25(OH)D concentration [28].
In the present study, the mean baseline levels were al-
most half in patients with intestinal malabsorption as com-
pared to the baseline levels found in healthy subjects. This
indicates the presence of vitamin D3 deficiency in the pa-
tient group as compared to healthy subjects. The primary
and the most important source of vitamin D is sunlight.
Although excessive exposure to sunlight and vitamin D
have been positively associated with non-melanoma skin
cancer [29], ecological studies suggest that sunlight may
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protect against female breast, ovarian, prostate, and colon
cancer [30]. Solar UV-B exposure and the amount of ex-
posure to sun are related inversely with cancer mortality
and survival in detailed epidemiological studies [31]. Some
analytical studies suggest a protective association between
circulating vitamin D in blood, which is largely derived
from sunlight or dietary vitamin D, and colorectal cancer
and prostate cancer [30]. However, looking at the overall
baseline levels of all participants in the present study, it
is also advisable to increase the moderate daily sun ex-
posure and to improve clothing apart from vitamin D3
supplementation.
Conclusion
We conclude that the buccal spray formulation was able
to increase mean serum vitamin D3 concentration sig-
nificantly higher as compared to the soft gelatin capsule,
in both healthy subjects (1.9 times) as well as in patients
with intestinal malabsorption syndrome (2.6 times).
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